BioSpace News Archive

Business

Sanofi to Eliminate 400 U.S. Jobs

Sanofi has announced major restructuring, which will involve layoffs.

January 22, 2018
·
2 min read
·
Mark Terry
Deals

Sanofi CEO Finally Scores With $11.6B Buyout of Biogen’s Spinoff Bioverativ

The deal has Sanofi paying $105 per share in cash.

January 22, 2018
·
3 min read
·
Mark Terry
Business

Bay Area’s Adamas Pharma Pays Big Bucks to Double HQ

With the commercial launch of newly-approved Parkinson’s disease treatment Gocovri, Bay Area drugmaker Adamas is growing.

January 22, 2018
·
2 min read
·
Alex Keown
Ascletis Plans $100M C Round; Then Hong Kong IPO

The company will use the money to fund clinical trials and develop a marketing operation.

January 22, 2018
·
1 min read
Business

FDA Furloughs 42% of Staff in Government Shutdown

The layoff leaves 58 percent of FDA employees on the job, which Gottlieb said is higher than the previous shutdown in 2013.

January 22, 2018
·
3 min read
·
Alex Keown
Business

Imaging3 Announces Addition of Dr. Douglas Beall to the Scientific Advisory Board

Dr. Beall brings both radiology and pain management experience to the SAB.

January 22, 2018
·
4 min read
Drug Development

Amgen Jumps as Migraine Drug Wows in Late-Stage Study

In the study, 246 patients were randomized to receive Aimovig or placebo over a 12-week treatment phase.

January 22, 2018
·
2 min read
·
Alex Keown
Deals

Deal Spree Continues as Celgene Nabs Juno in $9B Deal

The announcement sent shares of Juno soaring more than 27 percent in pre-market trading to $86.26.

January 22, 2018
·
2 min read
·
Alex Keown
Why Booming Celltrion Started Crashing Last Week

Celltrion, the little-known South Korean biotech company that surged into the ranks of the world’s most-traded stocks at the start of 2018, may finally be coming down to Earth.

January 22, 2018
·
1 min read
BioCapital

3 Diabetes Biotechs That Could Surge 50% or More in 2018

Wall Street projects these three biotechs will grow the fastest over the next 12 months.

January 22, 2018
·
1 min read